Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Maintains Buy on TaskUs, Lowers Price Target to $37

BTIG analyst Matt VanVliet maintains TaskUs (NASDAQ:TASK) with a Buy and lowers the price target from $45 to $37.

byBenzinga Newsdesk

August 9, 2022

1 minute read

BTIG analyst Matt VanVliet maintains TaskUs (NASDAQ:TASK) with a Buy and lowers the price target from $45 to $37.

Analyst Ratings

9 Analysts Have This to Say About Ambarella

By Benzinga Insights

Today, 3:05 AM

Within the last quarter, Ambarella (NASDAQ:AMBA) has observed the following analyst ratings:

AMBA

Analyst Ratings

Analyst Ratings For Elastic

By Benzinga Insights

Today, 3:05 AM

Analysts have provided the following ratings for Elastic (NYSE:ESTC) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

ESTC

Acutus Medical Completes Patient Enrolment In AcQForce Flutter IDE Trial

By Ragothaman Srinivasan

Today, 3:05 AM

Acutus Medical (NASDAQ: AFIB) completed patient enrollment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trial. The trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter.

AFIB